Results 61 to 70 of about 361,579 (250)

Carcinoid Syndrome and Carcinoid Heart Disease as Manifestations of Non-Metastatic Ovarian Neuroendocrine Tumour

Acta Médica Portuguesa, 2017
The carcinoid syndrome is rare but it is associated with carcinoid heart disease in more than a half of the cases. Carcinoid heart disease is typically characterised by morphological and functional modifications of right-sided valves.
Joana Simões-Pereira, Lai Mun Wang, Attila Kardos, Ashley Grossman   +3 more
doaj   +1 more source

mRNA profiling of a well-differentiated G1 pancreatic NET correlates with immunohistochemistry profile: a case report

BMC Gastroenterology, 2021
Background Neuroendocrine neoplasms (NENs) are a complex group of tumours that occur in many organs. Routinely used IHC markers for NEN diagnosis include CgA, synaptophysin, Ki67 and CD56.
Abhirami Venugopal, Jessie Gillick-Walker, Agnes Michalczyk, Mustafa Khasraw, M. Leigh Ackland   +4 more
doaj   +1 more source

Treatment sequence in patients with neuroendocrine tumours: a nationwide multicentre, observational analysis of the Swiss neuroendocrine tumour registry. [PDF]

, 2020
BACKGROUND In recent years, several treatment modalities have proved to be effective in the treatment of neuroendocrine tumours (NETs). However, there is currently no consensus on the sequence in which these options are best used.
Trepp, Roman, Lukas Bütikofer, Christoph Stettler, Roman Trepp, Kollár, Attila, Bütikofer, Lukas, Ochsenbein, Adrian, Attila Kollar, Adrian Ochsenbein, Stettler, Christoph   +9 more
core   +2 more sources

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Primary hepatic neuroendocrine tumour requiring live donor liver transplantation: case report and concise review

Annals of Hepatology, 2012
Primary hepatic neuroendocrine tumours are rare tumours effecting relatively young patients. As metastatic neuroendocrine tumours to the liver are much more common, extensive investigations are crucial to exclude a primary tumour elsewhere.
Ananta Gurung, Eric M. Yoshida, Charles H. Scudamore, Almoutaz Hashim, Siegfried R. Erb, Douglas L. Webber   +5 more
doaj   +1 more source

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

Pulmonary large cell carcinoma with neuroendocrine morphology shows genetic similarity to large cell neuroendocrine carcinoma

Diagnostic Pathology, 2022
Background Large cell neuroendocrine carcinoma (LCNEC) is a high-grade malignant pulmonary neuroendocrine tumour. The distinction of pulmonary large cell carcinoma (LCC) and LCNEC is based on the presence of neuroendocrine morphology and the expression ...
Zuoyu Liang, Weiya Wang, Qianrong Hu, Ping Zhou, Ying Zhang, Yuan Tang, Qian Wu, Yiyun Fu, Xue Li, Yang Shao, Lili Jiang   +10 more
doaj   +1 more source

Spatial biology in cancer epigenetics

Molecular Oncology, EarlyView.
Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley   +1 more source

Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care [PDF]

, 2019
Quality performance indicators (QPIs) are used to monitor the delivery of cancer care. Neuroendocrine tumours (NETs) are a family of individually uncommon cancers that derive from neuroendocrine cells or their precursors, and can occur in most organs ...
Parker, Kate, Lawrence, Ben, Siobhan Conroy, on behalf of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETs), Parker, Kate Elizabeth, on behalf of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETs),, Nick Pavlakis, Singh, Simron, Asif, Tahmina, Segelov, Eva, Ben Lawrence, Lo, Dorothy, Braden Woodhouse, Kate Parker, Meyer-Rochow, Goswin, Pavlakis, Nick, William Macdonald, Krämer, Nicole, Conroy, Siobhan, Asif, Tehmina, Simron Singh, Wakelin, Kate, Kong, Grace, Kate Wakelin, Tehmina Asif, Pattison, Sharon, Vallerie Gordon, Macdonald, William, Michael Michael, Dorothy Lo, Timothy Price, Koea, Jonathan, Woodhouse, Braden, Gordon, Vallerie, Sharon Pattison, Michael, Michael, Jonathan Koea, Price, Timothy, Grace Kong, Eva Segelov, Goswin Meyer-Rochow, Wyld, David, David Wyld, Nicole Kramer   +43 more
core   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source